

# PRODUCT INFORMATION



**LY293111**

Item No. 10009768

**CAS Registry No.:** 161172-51-6  
**Formal Name:** 2-[3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]4-yl)oxy]propoxy]-2-propylphenoxy]-benzoic acid  
**Synonyms:** Etalocib, VML 295

**MF:** C<sub>33</sub>H<sub>33</sub>FO<sub>6</sub>

**FW:** 544.6


**Purity:** ≥98%

**UV/Vis.:** λ<sub>max</sub>: 205, 256, 294 nm

**Supplied as:** A solution in methyl acetate

**Storage:** -20°C

**Stability:** ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

LY293111 is supplied as a solution in methyl acetate. To change the solvent, simply evaporate the methyl acetate under a gentle stream of nitrogen and immediately add the solvent of choice. Solvents such as ethanol, DMSO, and dimethyl formamide purged with an inert gas can be used. The solubility of LY293111 in these solvents is approximately 30 mg/ml.

LY293111 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, the methyl acetate solution of LY293111 should be diluted with the aqueous buffer of choice. LY293111 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

## Description

Leukotriene B<sub>4</sub> (LTB<sub>4</sub>) is a dihydroxy fatty acid derived from the 5-lipoxygenase pathway of arachidonic acid metabolism and is an important mediator of the inflammatory process. LY293111 is a potent antagonist of the LTB<sub>4</sub> receptor, BLT<sub>1</sub>, that inhibits the specific binding of radiolabeled-LTB<sub>4</sub> to isolated human neutrophils with an IC<sub>50</sub> value of 17.6 nM and inhibits the LTB<sub>4</sub>-induced chemotaxis of human neutrophils with an IC<sub>50</sub> value of 6.3 nM.<sup>1</sup> LY293111 inhibits growth of MiaPaCa-2 and AsPC-1 human pancreatic cancer cells *in vitro* (250-1,000 nM) and subcutaneous xenografts in athymic mice (250 mg/kg/day), inducing apoptosis and S-phase arrest.<sup>2</sup>

## References

1. Jackson, W.T., Froelich, L.L., Boyd, R.J., *et al.* Pharmacologic actions of the second-generation leukotriene B<sub>4</sub> receptor antagonist LY293111: *In vitro* studies. *J. Pharmacol. Exp. Ther.* **288**(1), 286-294 (1999).
2. Tong, W.-G., Ding, X.-Z., Hennig, R., *et al.* Leukotriene B<sub>4</sub> receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. *Clin. Cancer Res.* **8**, 3232-3242 (2002).

### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/13/2017

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM